Treating intermediate-risk prostate cancer with hypofractionated external beam radiotherapy alone

Radiotherapy and Oncology

Volumn 101, Issue 3, 2011, Pages 486-489

  Faria, Sergio ^a   Dal Pra, Alan ^a   Cury, Fabio ^a   David, Marc ^a   Duclos, Marie ^a   Freeman, Carolyn R ^a   Souhami, Luis ^a  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

Biochemical control; Hypofractionation; Intermediate risk; Prostate cancer; Radiotherapy; Toxicity

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BIOCHEMISTRY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RELAPSE; CANCER RISK; CANCER STAGING; DISEASE FREE SURVIVAL; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; GASTROINTESTINAL TOXICITY; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE FRACTIONATION; TUMOR VOLUME; UROGENITAL TRACT DISEASE;

AGED; AGED, 80 AND OVER; DOSE FRACTIONATION; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, CONFORMAL; RISK;

EID: 81855166965     PISSN: 01678140     EISSN: 18790887     Source Type: Journal    
DOI: 10.1016/j.radonc.2011.07.005     Document Type: Article

References (34)

1. I. Lee, and H. Sandler Hormone therapy and radiotherapy for intermediate risk prostate cancer Semin Radiat Oncol 18 2008 7 14
2. National Comprehensive Cancer Network Website. http://www.nccn.org/ professionals/physician-gls/f-guidelines.asp. Acessed in August, 2010.
3. S.L. Faria, L. Souhami, and H. Patrocinio Searching for optimal dose-volume constraints to reduce rectal toxicity after hypofractionated radiotherapy for prostate cancer Clin Oncol 22 2010 810 817
4. M.E. Poli, W. Parker, and H. Patrocinio An assessment of PTV margin definitions for patients undergoing conformal 3D external beam radiation therapy for prostate cancer based on an analysis of 10, 327 pretreatment daily ultrasound localizations Int J Radiat Oncol Biol Phys 67 2007 1430 1437
5. Common Termonology Criteria for Adverse Events (CTCAE), National Institute. http://www.fda.gov/cder/cancer/toxicityframe.htm. Acessed in August, 2010.
6. M. Roach 3rd, G. Hanks, and H. Thames Jr. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference Int J Radiat Oncol Biol Phys 65 2006 965 974
7. A.V. D'Amico, R. Whittington, and S.B. Malkowicz Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer JAMA 280 1998 969 974
8. I. Thompson, J.B. Thrasher, and G. Aus Guideline for the management of clinically localized prostate cancer: 2007 update J Urol 177 2007 2106 2131
9. E.A. Klein, J. Ciezki, P.A. Kupelian, and A. Mahadevan Outcomes for intermediate risk prostate cancer: are there advantages for surgery, external radiation, or brachytherapy? Urol Oncol 27 2009 67 71
10. R.G. Stock, S. Yalamanchi, S.J. Hall, and N.N. Stone Impact of hormonal therapy on intermediate risk prostate cancer treated with combination brachytherapy and external beam irradiation J Urol 183 2010 546 550
11. A.V. Taira, G.S. Merrick, and R.W. Galbreath Natural history of clinically staged low- and intermediate-risk prostate cancer treated with monotherapeutic permanent interstitial brachytherapy Int J Radiat Oncol Biol Phys 76 2010 349 354
12. W.J. Morris, M. Keyes, and D. Palma Population-based study of biochemical and survival outcomes after permanent 125I brachytherapy for low- and intermediate-risk prostate cancer Urology 73 2009 860 865
13. J.M. Martin, T. Rosewall, and A. Bayley Phase II trial of hypofractionated image-guided intensity-modulated radiotherapy for localized prostate adenocarcinoma Int J Radiat Oncol Biol Phys 69 2007 1084 1089
14. A.V. D'Amico, J. Manola, and M. Loffredo 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial JAMA 292 2004 821 827
15. P. Nickers, J. Hermesse, J.M. Deneufbourg, S. Vanbelle, and E. Lartigau Which α/β ratio and half-time of repair are useful for predicting outcomes in prostate cancer? Radiother Oncol 97 2010 462 466
16. D.P. Dearnaley, M.R. Sydes, and J.D. Graham Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial Lancet Oncol 8 2007 475 487
17. D.A. Kuban, S.L. Tucker, and L. Dong Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer Int J Radiat Oncol Biol Phys 70 2008 67 74
18. S.T. Peeters, W.D. Heemsbergen, and P.C. Koper Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy J Clin Oncol 24 2006 1990 1996
19. N. Rene, S. Faria, and F. Cury Hypofractionated radiotherapy for favorable risk prostate cancer Int J Radiat Oncol Biol Phys 77 2010 805 810
20. P.A. Kupelian, T.R. Willoughby, and C.A. Reddy Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience Int J Radiat Oncol Biol Phys 68 2007 1424 1430
21. H. Lukka, C. Hayter, and J.A. Julian Randomized trial comparing two fractionation schedules for patients with localized prostate cancer J Clin Oncol 23 2005 6132 6138
22. E.E. Yeoh, R.H. Holloway, and R.J. Fraser Hypofractionated versus conventionally fractionated radiation therapy for prostate carcinoma: updated results of a phase III randomized trial Int J Radiat Oncol Biol Phys 66 2006 1072 1083
23. G. Arcangeli, B. Saracino, and S. Gomellini A Prospective Phase III Randomized Trial of Hypofractionation Versus Conventional Fractionation in Patients With High-Risk Prostate Cancer Int J Radiat Oncol Biol Phys 78 2010 11 18
24. Dearnaley DP, Syndikis I, Norman AR, et al. Conventional or hypofractionated high dose intensity modulated radiotherapy in prostate cancer: Preliminary report on acute and late toxicity (ISRCTN97182923) - A phase III multicentre trial (CHHIP). 2007 Prostate Cancer Symposium: A Mutidisciplinary Approach, Orlando, FL. Abstract # 303. http://www.asco.org/ASCOv2/Meetings/ Abstracts?&vmview=abst-detail-view&confID=46&abstractID=20180. Acessed in May 2011.
25. Pollack A, Li T, Buyyounouski M, et al. Hypofractionation for Prostate Cancer: Interim Results of a Randomized Trial. 51st Annual ASTRO Meeting 2009. Int J Radiat Oncol Biol Phys [abstract] 2009;75 (issue 3- suppl): S81-S82.
26. O. Cahlon, M.J. Zelefsky, and A. Shippy Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: toxicity and biochemical outcomes Int J Radiat Oncol Biol Phys 71 2008 330 337
27. O. Zebentout, R. Apardian, and L. Beaulieu Clinical outcome of intermediate risk prostate cancer treated with iodine 125 monotherapy: The Hotel-Dieu of Quebec experience Cancer Radiother 14 2010 183 188
28. S.L. Faria, L. Souhami, and B. Joshua Reporting late rectal toxicity in prostate cancer patients treated with curative radiation treatment Int J Radiat Oncol Biol Phys 72 2008 777 781
29. N.S. Anderson, J.B. Yu, R.E. Peschel, and R.H. Decker A significant decrease in rectal volume and diameter during prostate IMRT Radiother Oncol 98 2011 187 191
30. J.A. Talcott, C. Rossi, and W.U. Shipley Patient-reported long-term outcomes after conventional and high-dose combined proton and photon radiation for early prostate cancer JAMA 303 2010 1046 1053
31. H.D. Thames, D. Kuban, and L.B. Levy The role of overall treatment time in the outcome of radiotherapy of prostate cancer: an analysis of biochemical failure in 4839 men treated between 1987 and 1995 Radiother Oncol 96 2010 6 12
32. McGowan D, Hunt D, Jones C, et al. Short-term Endocrine Therapy Prior to and during Radiation Therapy Improves Overall Survival in Patients with T1b-T2b Adenocarcinoma of the Prostate and PSA ≤20: Initial Results of RTOG 94-08 Int J Radiat Oncol Biol Phys [abstract] May 1, 2010;77:1.
33. Valicenti RK, Bae K, Michalski J, et al. Does adjuvant hormonal therapy improve freedom from biochemical relapse in prostate cancer patients receiving dose-escalated radiation therapy? An analysis of RTOG 9406. 2007 Prostate Cancer Symposium: A Mutidisciplinary Approach, Orlando, FL. Abstract # 297. http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst-detail- view&confID=46&abstractID=20134. Acessed in May 2011.
34. D.J. Demanes, D. Brandt, and L. Schour Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation Am J Clin Oncol 32 2009 342 347